Chugai Pharmaceutical Co., Ltd. (4519)

Frankfurt
Currency in EUR
51.6600
0.0000(0.00%)
Delayed Data·
4519 Scorecard
Full Analysis
Has raised its dividend for 4 consecutive years
Trading near 52-week High
Fair Value
Day's Range
43.110051.6600
52 wk Range
26.870051.6600
Key Statistics
Edit
Bid/Ask
46.00 / 56.00
Prev. Close
41.34
Open
43.16
Day's Range
43.11-51.66
52 wk Range
26.87-51.66
Volume
-
Average Volume (3m)
132
1-Year Change
76.98%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4519 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory
Show more

Chugai Pharmaceutical Co., Ltd. Company Profile

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology. The company was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Employees
5026
Market
Germany

Compare 4519 to Peers and Sector

Metrics to compare
4519
Peers
Sector
Relationship
P/E Ratio
35.5x17.4x−0.5x
PEG Ratio
1.880.150.00
Price/Book
7.2x1.4x2.6x
Price / LTM Sales
11.7x1.7x2.9x
Upside (Analyst Target)
-20.1%66.0%
Fair Value Upside
Unlock17.0%10.6%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 235.39%
Dividend Yield
2.16%
Industry Median 1.51%
Annualised payout
1.118
Paid unevenly
5-Years Growth
+25.09%
Growth Streak

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Chugai Pharmaceutical (4519) Stock Price Today?

The Chugai Pharmaceutical stock price today is 51.66.

What Stock Exchange Does Chugai Pharmaceutical Trade On?

Chugai Pharmaceutical is listed and trades on the Frankfurt stock exchange.

What Is the Stock Symbol for Chugai Pharmaceutical?

The stock symbol for Chugai Pharmaceutical is "4519."

Does Chugai Pharmaceutical Pay Dividends? What’s The Current Dividend Yield?

The Chugai Pharmaceutical Co., Ltd. dividend yield is 2.16%.

What Is the Chugai Pharmaceutical Market Cap?

As of today, Chugai Pharmaceutical market cap is 85.87B.

What is Chugai Pharmaceutical Earnings Per Share?

The Chugai Pharmaceutical EPS is 235.39.

From a Technical Analysis Perspective, Is 4519 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.